Effect of KCN potassium channel gene on lipid metabolism in mice

doi:10.3969/j.issn.1006-7795.2017.02.004

Abstract

Abstract: Objective To study the effect of potassium channel gene (KCN) on lipid metabolism in mice and its related signal pathway and to provide a new therapeutic target for dyslipidemia in diabetes. Methods Our group constructed KCN channel knock-out mouse model. In this study, KCN channel knock-out mice and control C57BL/6 mice will be examined. We will detect total cholesterol, triglyceride, high-density lipoprotein and low-density lipoprotein in their serum, the protein level of adenosine 5'-monophosphate (AMP)-activated protein kinase (AMPK) pathway from rat's tissue was detected by western blot and the level of hepatic steatosis will be observed by HE staining. Results The serum levels of total cholesterol, triglyceride and low-density lipoprotein in KCN gene knock-out mouse were all significantly higher than those in controls, and high-density lipoprotein is lower than control (P<0.05). The results of Western blotting showed that phosphate-protein kinase B (Phos-AKT) and phos-AMPK levels in liver tissue of KCN gene knockout mice were lower than those in normal control group, and phosphate-acetyl CoA carboxylase (phos-ACCα) level was significantly higher (P<0.05). Conclusion KCN channel influences lipid metabolism in mice by classical fatty acid oxidation AMPK pathway.

Key words: potassium voltage-gated channel, lipid metabolism, adenosine 5'-monophosphate (AMP)-activated protein kinase pathway

CLC Number:

R589.2

Liu Jingyi, Lu Jing, Yang Jinkui. Effect of KCN potassium channel gene on lipid metabolism in mice[J]. Journal of Capital Medical University, 2017, 38(2): 161-166.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.02.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I2/161

References

[1] Liman E R, Tytgat J, Hess P. Subunit stoichiometry of a mammalian K⁺ channel determined by construction of multimeric cDNAs[J]. Neuron,1992, 9(5): 861-871.
[2] Hardy A B, Fox J E, Giglou P R, etal. Characterization of Erg K+ channels in α-and β-cells of mouse and human islets[J]. Biol Chem, 2009, 284(144): 30441-30452.
[3] Qiu H Y, Yuan S S, Yang F Y, et al. HERG protein plays a role in moxifloxacin-induced hypoglycemia [J]. J Diabetes Res, 2016,16(6): 298-304.
[4] Kudo N,Gillespie J G,Kung L, et al.C haracterization of 50AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia [J].Biochim Biophys Acta, 1996, 1301(1-2): 67-75.
[5] Ye J M, Dzamko N, Cleasby M E, et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin [J]. Diabetologia, 2004, 47(7):1306-1313.
[6] Fryer L G, Carling D. AMP-activated protein kinase and the metabolic syndrome [J]. Biochem Soc Trans, 2005, 33(2):362-366.
[7] Gonzalez A A, Kumar R, Mulligan, et al. Metabolic adaptations to fasting and chronic caloric restriction in heart, muscle, and liver do not include changes in AMPK activity [J]. Am J Physiol Endocrinol Metab,2004, 287(5): 1032-1037.
[8] Weickert M O, Pfeiffer A F. Signalling mechanisms linking hepatic glucose and lipid metabolism [J]. Diabetologia, 2006, 49 (8): 1732-1741.
[9] Hardie D G. The AMP-activated protein kinase pathway new players upstream and downstream [J]. J Cell Sci, 2004,117 (23):5479-5487.
[10] Jampvska A, Hatzinikolas G. AMPK and ACC phosphorylation: Effect of leptin, muscle fibre type and obesity [J].Mol Cell Endocrinol, 2008, 284(1-2): 1-10.
[11] 解雪芬,朱毅. AMPK与代谢综合征[J]. 基础医学与临床,2006,26 (1): 27-34.
[12] 王楚媛,孔令芳,侯永生,等.脂联素与2型糖尿病进程的相关性[J]. 中国医科大学学报,2014,(5):429-431,436.
[13] 马娜敏,于世林,耿亚辉,等.北京温泉社区中老年2型糖尿病人群伴发代谢综合征的患病率及分布特征[J]. 首都医科大学学报, 2014,35 (1):56-59.
[14] Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders [J]. J Physiol, 2006, 574 (1): 41-53.
[15] Bourbeau,Bartberger. Recent advances in the development of acetyl-CoA carboxylase (ACC) inhibitors for the treatment of metabolic disease [J]. J Med Chem, 2015, 58(2): 525-536.
[16] Muhlbauera E, Bazwinsky I, Wolgasta S, et al. Circadian changes of ether-a-go-go-related-gene (Erg) potassium channel transcripts in the rat pancreas and β-cell[J]. Cell Mol Life Sci, 2007, 64(6): 768-780.